BiomX Inc.

Equities

PHGE

US09090D1037

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
0.358 ^USD	+5.29%		+6.71%	+27.86%

21/05	Transcript : BiomX Inc., Q1 2024 Earnings Call, May 21, 2024
20/05	BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

CF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy

January 04, 2022 at 05:45 pm IST

The Cystic Fibrosis Foundation announced that it has awarded up to $5 million to BiomX Inc. to conduct a Phase 1b/2a clinical trial to test the safety and tolerability of bacteriophage (phage therapy) in Pseudomonas aeruginosa infections in people living with cystic fibrosis.

Latest news about BiomX Inc.

Transcript : BiomX Inc., Q1 2024 Earnings Call, May 21, 2024	21/05
BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05	CI
Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board	18/04	CI
Transcript : BiomX Inc., Q4 2023 Earnings Call, Apr 03, 2024	03/04
BiomX Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03/04	CI
Biomx Inc. Announces Board Changes	18/03	CI
BiomX Inc. announced that it has received $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC	15/03	CI
BiomX Inc. completed the acquisition of Adaptive Phage Therapeutics, Inc.	15/03	CI
Sector Update: Health Care Stocks Advance Wednesday Afternoon	07/03	MT
Sector Update: Health Care	07/03	MT
BiomX Shares Rally After Merger Deal With Adaptive Phage Therapeutics	06/03	MT
Transcript : BiomX Inc., Adaptive Phage Therapeutics, Inc. - M&A Call	06/03
BiomX Inc. announced that it expects to receive $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC	06/03	CI
BiomX Inc. agreed to acquire Adaptive Phage Therapeutics, Inc. for $11.5 million.	06/03	CI
BiomX Says Data From Phase 1b/2a Trial of BX004 Showed 'Meaningful' Improvement in Pulmonary Function	29/11	MT
Transcript : BiomX Inc. - Special Call	29/11
Biomx Announces Positive Topline Results from Part 2 of the Phase 1B/2A Trial Evaluating Bx004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis	29/11	CI
BiomX Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Biomx to Present Data from Ongoing Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis	27/23/27	CI
BiomX Inc. Announces the Appointment of Edward L. Williams to its Board of Directors	18/23/18	CI
BiomX Inc. Announces Completion of Patient Dosing in Part 2 of Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis	04/23/04	CI
Transcript : BiomX Inc., Q2 2023 Earnings Call, Aug 09, 2023	09/23/09
BiomX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Biomx Inc. to Present Part 1 Data from Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session At The46th European Cystic Fibrosis Conference	31/23/31	CI
BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI

Chart BiomX Inc.

Duration

Period

More charts

Company Profile

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.358 USD

Average target price

2.167 USD

Spread / Average Target

+505.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOMX INC.	+27.86%	2.37Cr
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	13TCr
REGENERON PHARMACEUTICALS, INC.	+24.67%	12TCr
ARGENX SE	+25.44%	2.77TCr
BIONTECH SE	-17.74%	2.03TCr
GENMAB A/S	-15.17%	1.68TCr
BEIGENE, LTD.	-15.21%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+11.91%	1.48TCr
WUXI APPTEC CO., LTD.	-47.10%	1.46TCr
SAREPTA THERAPEUTICS, INC.	+54.50%	1.44TCr

Bio Therapeutic Drugs